Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Evaluating the short-term effect of gefitinib in advanced lung adenocarcinoma with positive EGFR-mutant by dual source volume perfusion CT].

Zhonghua yi xue za zhi - 1 Nov 2011

Xiong Zeng, Hu Cheng-ping, Liu Jin-kang, Lu Rong-li, Zhou Hui, Zhou Mo-ling, Chen Wei

Abstract excerpt

OBJECTIVE: To investigate tumor vascularity by dual source volume perfusion computed tomography (VPCT) in advanced lung adenocarcinoma with positive EGFR-mutant and determine whether any of the VPCT parameters would predict the tumor response to gefitinib. METHODS: Twelve patients (5 males and 7 females, Median age: 53 years, range: 36 - 69 years) with advanced lung adenocarcinoma received VPCT scan. All patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to ErbB Receptors

Share to Gefitinib

Share to Lung Neoplasms

Share to Quinazolines

Share to Treatment Outcome

Source

Identifiers

PMID: 22333542

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

[Evaluating the short-term effect of gefitinib in advanced lung adenocarcinoma with positive EGFR-mutant by dual source volume perfusion CT].PMID 22333542Read ↗

The pharmacokinetics and long-term therapeutic effects of gefitinib in patients with lung adenocarcinoma harboring the epidermal growth factor receptor(EGFR)mutation.Semantic proximity Read ↗

Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.Semantic proximity Read ↗

Dual inhibition of EGFR‑VEGF: An effective approach to the treatment of advanced non‑small cell lung cancer with EGFR mutation (Review).Semantic proximity Read ↗

CT delta-radiomics for identification of advanced EGFR-Mutated lung adenocarcinoma Sensitive to Therapies Targeting EGFR PathwaySemantic proximity Read ↗

Combined Spectral CT and Perfusion CT for Noninvasive Prediction of EGFR Mutation Status in Non-Small Cell Lung CancerSemantic proximity Read ↗

Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutationSemantic proximity Read ↗

Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study.Semantic proximity Read ↗

Radiomics Analysis to Enhance Precise Identification of Epidermal Growth Factor Receptor Mutation Based on Positron Emission Tomography Images of Lung Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.